Compare · BASI vs MEDP
BASI vs MEDP
Side-by-side comparison of Bioanalytical Systems, Inc. (BASI) and Medpace Holdings Inc. (MEDP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BASI and MEDP operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP carries a market cap of $18.37B.
- MEDP has hit the wire 6 times in the past 4 weeks while BASI has been quiet.
- MEDP has more recent analyst coverage (25 ratings vs 0 for BASI).
- Company
- Bioanalytical Systems, Inc.
- Medpace Holdings Inc.
- Price
- -
- -
- Market cap
- -
- $18.37B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1997
- 2016
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 25
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest BASI
- SEC Form RW filed by Bioanalytical Systems, Inc.
- SEC Form 8-K filed by Bioanalytical Systems, Inc.
- Bioanalytical Systems, Inc. Announces Corporate Name Change to Inotiv, Inc.
- Bioanalytical Systems, Inc., doing business as Inotiv, Announces Plan to Expand Service Offerings to Include Cardiovascular Safety Pharmacology
- Bioanalytical Systems, Inc., doing business as Inotiv, Invests in Additional Vivarium Capacity at Facility in West Lafayette, IN
- SEC Form 8-K filed
- Colliers Securities resumed coverage on Bioanalytical Systems with a new price target
- SEC Form 4: Beth Taylor bought $88,500 worth of Common Shares (5,000 units at $17.70), increasing direct ownership by 17% to 34,295 units
- Bioanalytical Systems, Inc., doing business as Inotiv, to Participate in the H.C. Wainwright Global Life Sciences Virtual Conference
- SEC Form EFFECT filed
Latest MEDP
- General Counsel & Corp. Secy. Ewald Stephen P sold $859,050 worth of shares (1,245 units at $690.00), decreasing direct ownership by 6% to 19,098 units (SEC Form 4)
- Exec. VP, Operations Burwig Susan E sold $13,540,000 worth of shares (20,000 units at $677.00) (SEC Form 4)
- SEC Form 4 filed by Medpace Holdings Inc.
- SEC Form 10-Q filed by Medpace Holdings Inc.
- SEC Form 8-K filed by Medpace Holdings Inc.
- Medpace Holdings, Inc. Reports Third Quarter 2026 Results
- SEC Form 4 filed by Medpace Holdings Inc.
- SEC Form 4 filed by Medpace Holdings Inc.
- Director Mccarthy Cornelius P. Iii converted options into 28 shares, increasing direct ownership by 0.23% to 12,303 units (SEC Form 4)
- Director Kraft Robert O. converted options into 32 shares, increasing direct ownership by 3% to 987 units (SEC Form 4)